Our meta-analysis results showed that plasmapheresis used as an adjunct to chemotherapy had a benefit in the management of dialysisdependent multiple myeloma patients with renal failure.

Background To evaluate the outcomes of pancreaticogastrostomy and pancreaticojejunostomy after pancreatoduodenectomy with the help of a meta-analysis. Methods Randomized controlled trials comparing pancreaticogastrostomy and pancreaticojejunostomy were searched electronically using PubMed, The Cochrane Library, and EMBASE. Fixed and random-effects were used to measure pooled estimates. Research indicators included pancreatic fistula, delayed gastric emptying, postoperative hemorrhage, intraperitoneal fluid collection, wound infection, overall postoperative complications, reoperation, and mortality. Results Overall, 10 randomized controlled trials were included in this meta-analysis, with a total of 1629 patients. The overall incidences of pancreatic fistula and intra-abdominal collections were lower in the pancreaticogastrostomy group than in the pancreaticojejunostomy group (OR=0.73, 95% CI 0.55~0.96, p=0.02; OR=0.59, 95% CI 0.37~0.96, p=0.02, respectively). The incidence of B/C grade pancreatic fistula in the pancreaticogastrostomy group was lower than that in the pancreaticojejunostomy group, but no significant difference was observed (OR=0.61, 95%CI 0.34~1.09, p=0.09). Postoperative hemorrhage was more frequent in the pancreaticogastrostomy group than in the pancreaticojejunostomy group (OR=1.52; 95% CI 1.08~2.14, p=0.02). No significant differences in terms of delayed gastric emptying, wound infection, reoperation, overall postoperative complications, mortality, exocrine function, and hospital readmission were observed between groups. Conclusion This meta-analysis suggests that pancreaticogastrostomy reduces the incidence of postoperative pancreatic fistula and intraperitoneal fluid collection but increases the risk of postoperative hemorrhage compared with pancreaticojejunostomy.

Purpose To investigate the prognostic value of NDRG1 and the relationship between NDRG1 and immunoinfiltration. Meanwhile, the expression of NDRG1 in gastric cancer was investigated.Methods A comprehensive analysis of the relationship between NDRG1 gene and prognosis of various cancers, tumor mutational burden (TMB), microsatellite instability (MSI) and immune cell infiltration was conducted by using a range of bioinformatics methods on the basis of existing public databases as a mean to investigate the potential prognostic value of NDRG1 in pan-carcinoma. At the same time, 40 gastric cancer tissues and paracancer tissue specimens were collected. The expression of NDRG1 in gastric cancer tissues and adjacent tissues were verified by experiments. R software and GraphPad Prism 8 software were used for statistical analysis and mapping.Results NGRG1 was shown to be weakly expressed in BRCA, STAD, THCA, while it was shown to be highly expressed in CHOL, HNSC, KIRC, LIHC and LUSC. The survival rate of patients with high expression of NDRG1 in BRCA, LIHC and LUAD was lower than that of patients with low expression of NDRG1. However, patients with high expression of NDRG1 in KIRC had better survival than those with low expression of NDRG1. The expression of NDPG1 was positively correlated with TMB in CESC, BRCA, ACC, UCEC, SARC, PAAD and KIRC, but negatively correlated with TMB in THCA, SKCM, PRAD, PCPG and LGG. The expression of NDRG1 was positively correlated with MSI in COAD, BRCA, UCEC, SARC, PAAD and LUSC, and negatively correlated with MSI in PRAD. In addition, the results of the study indicated that NDRG1 was low expressed in gastric cancer tissues, high expressed in paracancer tissues and mainly distributed in cytoplasm (P = 0.0002). In terms of the degree of differentiation, the expression level of NDRG1 protein in moderately differentiated and highly differentiated gastric cancer tissues was higher than that in undifferentiated and poorly differentiated groups (P = 0.038). In terms of tumor invasion, NDRG1 expression in T1-T2 group was significantly higher than that in T3-T4 group (P = 0.025). In clinicopathologic stage, the expression of NDRG1 in stage I-II was significantly higher than that in stage III-IV (P = 0.024).Conclusion NDRG1 can be used as a prognostic marker in multiple cancers. NDRG1 was low expressed in gastric cancer tissues and high expressed in paracancer tissues. High expression of NDRG1 was associated with favorable pathological features of gastric cancer, which may be involved in inhibiting the occurrence and development of gastric cancer.